Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study to evaluate first-line maintenance treatment with Rubraca + Opdivo, Rubraca, Opdivo and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency (HRD)

Next Previous
Trial Profile

A phase III study to evaluate first-line maintenance treatment with Rubraca + Opdivo, Rubraca, Opdivo and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency (HRD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Rucaparib (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 26 Feb 2018 According to a Clovis Oncology media release, this study is sponsored by Bristol-Myers Squibb and is expected to begin in the first half of 2018.
  • 01 Nov 2017 According to a Clovis Oncology media release, this trial is expected to begin in early 2018.
  • 02 Aug 2017 According to a Clovis Oncology media release, apart from the U.S., Europe the trial could possibly conducted in additional countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top